Kennedy urges overseas Rx database

Share this article:
Sen. Edward Kennedy (D-MA) says the FDA should build databases to enable it to determine where drug companies obtain their ingredients and what they are doing to ensure the ingredients are pure and potent. And he is asking drug trade associations to urge their members to provide information to the FDA.

Kennedy suggested the FDA action in March letters to FDA commissioner Andrew von Eschenbach and the CEOs of PhRMA, Biotechnology Industry Organization, Generic Pharmaceutical Association and Consumer Healthcare Products Association.

Kennedy said his recommendation comes as a result of the deaths of 19 people from reactions to contaminated Heparin. In his letters, Kennedy said it “appears likely” that hypersulfated chondroitin sulfate was “added intentionally to protect the sales of Heparin. Pigs are the source of Heparin but are in short supply in China because of rampant disease, which may have led to use of the contaminant.”
He noted that 80% of the active ingredients in US drugs are derived from overseas sources, with 40% from China and India.

Kennedy also told von Eschenbach he believes those responsible for the Heparin incident should be held accountable and urged the FDA to work with the Justice Department in its investigation and to pursue enforcement actions.

Meanwhile, Sen. Charles Schumer (D-NY) has said he and Kennedy are introducing legislation to increase FDA funding for foreign inspections and require overseas monitoring. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?